Dr Margo R. Roberts | Chief Scientific Officer
Kite Pharma Inc

Dr Margo R. Roberts, Chief Scientific Officer, Kite Pharma Inc

Dr. Roberts has more than two decades of biomedical research, drug discovery and development experience. From 1999 to 2013, Dr. Roberts held an Associate Professor position at the University of Virginia where she pursued interdisciplinary research in the area of immunity and inflammation. From 1990 to 1998, she served as Principal Scientist and Director of Immune and Cell Therapy at Cell Genesys, Inc. Dr. Roberts is the inventor on the first set of CAR patents, including second-generation CAR constructs that incorporate the costimulatory domains of receptors, such as CD28, aimed at improving CAR T cell survival and function. She is the author of more than 25 scientific publications and inventor on 13 issued US patents and three published US patent applications related to CAR technology and tumor vaccine therapies. Dr. Roberts was a postdoctoral fellow at Yale and at the LGME of the CNRS in France. She received her BSc with honors and her PhD from the University of Leeds in England.


DC Co-conference Day 3 April 5 @ 09:10

Panel: Engineering CAR-T & TCR cells for cancer therapy

  • How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?
  • The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product
  • The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?
  • Mitigating side effects: controlling neurotoxicity etc.
  • Biomarkers – Identifying patients that will respond to treatment
  • Combination strategies

back to speakers